Sustained Release Innovation for HIV (SRI) (R61/R33 Clinical Trial Optional)

End Date: 
Dec 01 2018
Grant Type: 
Grant Source: 

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA requires an industry partner, milestones linked to Go/No-Go decisions and year 5 funding requires submission of a pre-IND application to the FDA.